Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed on B-cells. Originally developed for the treatment of B-cell lymphomas, rituximab has become one of the most widely used therapeutic antibodies in medicine, with applications extending from hematological malignancies to a broad range of autoimmune disorders["@cd20_biology"].
In the context of neurodegenerative diseases, rituximab represents an attempt to target the B-cell component of the immune system that may contribute to neurodegeneration in certain conditions. By depleting CD20-positive B-cells, the antibody reduces autoantibody production, antigen presentation, and inflammatory cytokine release—all mechanisms that may be relevant in conditions where immune dysregulation contributes to neuronal damage.
Mechanism of Action
Rituximab exerts its therapeutic effects through multiple complementary mechanisms[@b_cell_depletion]:
CD20 Targeting
...
Overview
Mermaid diagram (expand to render)
Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed on B-cells. Originally developed for the treatment of B-cell lymphomas, rituximab has become one of the most widely used therapeutic antibodies in medicine, with applications extending from hematological malignancies to a broad range of autoimmune disorders["@cd20_biology"].
In the context of neurodegenerative diseases, rituximab represents an attempt to target the B-cell component of the immune system that may contribute to neurodegeneration in certain conditions. By depleting CD20-positive B-cells, the antibody reduces autoantibody production, antigen presentation, and inflammatory cytokine release—all mechanisms that may be relevant in conditions where immune dysregulation contributes to neuronal damage.
Mechanism of Action
Rituximab exerts its therapeutic effects through multiple complementary mechanisms[@b_cell_depletion]:
CD20 Targeting
CD20 Expression:
CD20 is a surface antigen expressed on most mature B-cells
Expressed from pre-B-cell stage through mature B-cells
Not expressed on plasma cells (which produce antibodies)
This pattern allows B-cell depletion while sparing antibody-producing plasma cells
Antibody Structure:
Chimeric antibody with murine variable regions and human IgG1 Fc
Designed for optimal effector function
Mediates complement activation and antibody-dependent cellular cytotoxicity
Complement-Dependent Cytotoxicity (CDC)
Mechanism:
Rituximab bound to CD20 activates the classical complement pathway
Formation of membrane attack complex (MAC)
Direct lysis of B-cells
Particularly effective against cells with high CD20 density
Antibody-Dependent Cellular Cytotoxicity (ADCC)
Mechanism:
Fc portion of rituximab engages Fcγ receptors on natural killer cells, macrophages, and neutrophils
These effector cells destroy rituximab-coated B-cells
ADCC is a major mechanism of B-cell depletion in vivo
Direct Effects on B-cell Function
Apoptosis Induction:
Cross-linking of CD20 by rituximab can directly induce apoptosis
Contributes to B-cell depletion independent of immune effector mechanisms
Function Modulation:
May modulate B-cell receptor signaling
Reduces B-cell activation and proliferation
Clinical Applications in Neurodegeneration
Multiple System Atrophy
MSA is a rapidly progressive neurodegenerative disorder characterized by parkinsonian, cerebellar, and autonomic features. Evidence of B-cell involvement has motivated investigation of rituximab[@krismer2021]:
Rationale:
B-cells have been implicated in the pathogenesis of MSA
Autoantibodies against neural antigens detected in some patients
Glial pathology may have immune components
Rationale for B-cell targeting
Clinical Evidence:
Phase II trials have investigated rituximab in MSA
Some studies showed benefit in motor symptoms
Results have been variable across studies
Larger controlled trials are needed
Outcomes:
May slow disease progression in some patients
Effects more pronounced in early disease stages
Not yet established as standard treatment
Progressive Supranuclear Palsy
PSP is a tauopathy characterized by tau accumulation in subcortical and brainstem regions. While primarily a proteinopathy, immune mechanisms may contribute[@holmy2019]:
Rationale:
Microglial activation documented in PSP brains
Possible B-cell involvement in disease pathogenesis
Theoretical basis for immune modulation
Clinical Evidence:
Limited trials of rituximab in PSP
Mixed results across studies
Some patients showed slowed progression
Insufficient evidence for routine use
Amyotrophic Lateral Sclerosis
ALS involves progressive loss of motor neurons. Immune dysregulation, including potential autoimmune components, has been implicated[@miller2020]:
Rationale:
T-cell abnormalities in ALS
Potential for autoimmune-mediated motor neuron damage
Microglial activation contributes to neurodegeneration
Clinical Evidence:
Trials of rituximab in ALS have been conducted
Results have been generally negative
No clear benefit demonstrated
Not used clinically for ALS
Paraneoplastic Neurological Disorders
Rituximab is established in the treatment of paraneoplastic neurological syndromes: